Clinical trial
Bexarotene in Treating Patients With Metastatic Breast Cancer
NCT00003752 · Ligand Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00003752 |
|---|---|
| Title | Bexarotene in Treating Patients With Metastatic Breast Cancer |
| Official title | A Multicenter Phase II Evaluation of Targretin (Bexarotene) Capsules in Patients With Advanced Breast Cancer |
| Lead sponsor | Ligand Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug |
| Interventions | bexarotene |
| Enrollment | 180 |
| Start date | Oct 1, 1998 |
| Completion | Mar 1, 2003 |
| First posted | May 25, 2004 |
| Last update posted | May 30, 2013 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: